Barclays PLC Purchases 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Barclays PLC boosted its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 162.2% in the 3rd quarter, Holdings Channel reports. The firm owned 50,210 shares of the company’s stock after buying an additional 31,057 shares during the quarter. Barclays PLC’s holdings in Lexeo Therapeutics were worth $454,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Janus Henderson Group PLC raised its holdings in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after buying an additional 599,203 shares during the period. Point72 Asset Management L.P. bought a new position in Lexeo Therapeutics in the 3rd quarter valued at $3,348,000. Verition Fund Management LLC increased its stake in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after purchasing an additional 355,928 shares during the period. Ikarian Capital LLC bought a new stake in shares of Lexeo Therapeutics during the third quarter worth $2,325,000. Finally, State Street Corp boosted its stake in shares of Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after purchasing an additional 57,674 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Trading Up 9.3 %

NASDAQ:LXEO opened at $7.29 on Friday. The firm has a 50-day simple moving average of $7.31 and a 200-day simple moving average of $10.21. Lexeo Therapeutics, Inc. has a one year low of $5.77 and a one year high of $22.33. The firm has a market cap of $241.05 million and a P/E ratio of -2.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 10,000 shares of company stock valued at $80,550 over the last 90 days. Corporate insiders own 4.50% of the company’s stock.

Analysts Set New Price Targets

LXEO has been the topic of several recent analyst reports. HC Wainwright raised their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Chardan Capital raised their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners lowered their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.80.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.